We came across a bullish thesis on Biohaven Ltd. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on BHVN. Biohaven Ltd.’s share was trading at $11.54 as of February 18th.
Photographee.eu/Shutterstock.com
Biohaven Ltd. is a clinical-stage biotechnology company targeting large global markets with significant unmet needs across neurology, immunology, and oncology, with lead programs such as its Kv7 activator franchise representing...
